Month: November 2022

On August 31, 2002, Wang, Jingkang; Liu, Yong; Yin, Qiuxiang published an article.Formula: C17H21ClFN3O4 The title of the article was Studies on the mechanism of primary nucleation of ciprofloxacin hydrochloride monohydrate. And the article contained the following:

A general expression for the relation between induction period and supersaturation was developed based on polynuclear approach. Different mechanism of primary nucleation in solution can be illustrated by the expression. The results of induction period determined by laser scattering method shows that the crystallization of ciprofloxacin hydrochloride monohydrate in water/ethanol or aqueous solution is by the mechanism of primary nucleation followed by one-dimensional diffusion growth, and then one-dimensional continuous or “birth and spread” growth on crystal face. The growth mechanism on the crystal face is affected by temperature and solvent. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Formula: C17H21ClFN3O4

The Article related to ciprofloxacin hydrochloride monohydrate primary nucleation mechanism, Unit Operations and Processes: Separation Processes and other aspects.Formula: C17H21ClFN3O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Deka, Nabajyoti; Bajare, Swapnil; Anthony, Jessy; Nair, Amrutha; Damre, Anagha; Patel, Dharmeshkumar; B.-Rao, Chandrika; Sivaramakrishnan, H.; Mutt, Shivaprakash Jagalur; Wilankar, Chandan; Marita, Rosalind published an article in 2013, the title of the article was Synthesis of N-(6-(4-(piperazin-1-yl)phenoxy)pyridin-3-yl)benzenesulfonamide derivatives for the treatment of metabolic syndrome.Recommanded Product: 67914-60-7 And the article contains the following content:

Metabolic syndrome is a widely prevalent multifactorial disorder associated with an increased risk of cardiovascular disease and type 2 diabetes mellitus. High plasma levels of insulin and glucose due to insulin resistance are a major component of the metabolic disorder. Thiazolidinediones (TZDs) are potent PPARγ ligands and used as insulin sensitizers in the treatment of type 2 diabetes mellitus. They are potent insulin-sensitizing agents but due to adverse effects like hepatotoxicity, a safer alternative of TZDs is highly demanded. The synthesis of N-(6-(4-(piperazin-1-yl)phenoxy)pyridin-3-yl)benzenesulfonamide derivatives I (R = 2,4-Cl2C6H3, 2,5-(OCH3)2C6H3, 2-thienyl, etc.) an alternate remedy for insulin resistance is reported. The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).Recommanded Product: 67914-60-7

The Article related to piperazinyl pyridinyl benzenesulfonamide preparation metabolic syndrome, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Recommanded Product: 67914-60-7

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 17, 2001, Talwar, Naresh; Sen, Himadri; Staniforth, John N. published a patent.Related Products of 86393-32-0 The title of the patent was Orally administered controlled drug delivery system providing temporal and spatial control. And the patent contained the following:

A pharmaceutical composition in the form of tablets or capsules provides a combination of temporal and spatial control of drug delivery to a patient for effective therapeutic results. The pharmaceutical composition comprises a drug, a gas generating component, a swelling agent, a viscolyzing agent, and optionally a gel forming polymer. The swelling agent belongs to a class of compounds known as super-disintegrants (e.g., cross-linked polyvinylpyrrolidone or sodium CM-cellulose). The viscolyzing agent initially and the gel forming polymer thereafter form a hydrated gel matrix which entraps the gas, causing the tablet or capsule to be retained in the stomach or upper part of the small intestine (spatial control). At the same time, the hydrated gel matrix creates a tortuous diffusion path for the drug, resulting in sustained release of the drug (temporal control). A preferred once daily ciprofloxacin formulation comprises 69.9 ciprofloxacin base, 0.34 sodium alginate, 1.03 xanthan gum, 13.7 sodium bicarbonate, 12.1 cross-linked polyvinylpyrrolidone, and optionally other pharmaceutical excipients, the formulation being in the form of a coated or uncoated tablet or capsule. A tablet contained ranitidine hydrochloride (I) 300.00, xanthan gum (Keltrol TF) 20.00, sodium alginate (Keltone LVCR) 20.00, cross-linked CM-cellulose 50.00, sodium bicarbonate 50.00, magnesium stearate 5.00, and talc 5.00%. The % cumulative release of I from the tablets was 84.37% after 8 h. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Related Products of 86393-32-0

The Article related to oral controlled drug delivery system, ranitidine controlled release tablet, Pharmaceuticals: Formulation and Compounding and other aspects.Related Products of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 24, 2019, Bonacucina, Giulia; Cespi, Marco; Casettari, Luca; Torregiani, Elisabetta; Logrippo, Serena; Palmieri, Giovanni Filippo; Perinelli, Diego Romano; Ganzetti, Roberta; Sestili, Matteo published a patent.Application of 86393-32-0 The title of the patent was Gel formulations containing water-soluble active ingredients for oral administration of drugs in patients with dysphagia. And the patent contained the following:

A pharmaceutical gel formulation is disclosed containing water soluble therapeutically active ingredient which are generally available only as oral solid dosage forms or tablets and/or capsules and/or immediate release powders or granules, which can be administered in the presence of abnormalities in the swallowing process. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Application of 86393-32-0

The Article related to formulation gel oral dysphagia tablet capsules powder granule pharmaceutical, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2017, Le, Tien Canh published a patent.Formula: C17H21ClFN3O4 The title of the patent was Dual-rate release formulation with high drug loading comprising anionic polysaccharide amino acid complex, and preparation thereof. And the patent contained the following:

The present document describes a pharmaceutical excipient composition comprising a functionalized anionic polysaccharide having carboxyl groups complexed with an amino acid-divalent cation complex, monolithic solid dosage forms for dual rate release of an active pharmaceutical ingredient, comprising the pharmaceutical excipient composition and active pharmaceutical ingredients, as well as processes for preparing the pharmaceutical excipient composition The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Formula: C17H21ClFN3O4

The Article related to anionic polysaccharide amino acid complex dual rate pharmaceutical excipient, Pharmaceuticals: Formulation and Compounding and other aspects.Formula: C17H21ClFN3O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On September 4, 2003, Petereit, Hans-Ulrich; Meier, Christian; Gryczke, Andreas published a patent.Product Details of 86393-32-0 The title of the patent was Melt extrusion consisting of salts of active ingredients and (meth)acrylate copolymer. And the patent contained the following:

The invention relates to a method for producing active ingredient-containing granules or powders involving the following steps: (a) melting a mixture consisting of a pharmaceutically active ingredient and of a (meth)acrylate copolymer, which is comprised of 40-75 weight% of radically polymerized C1-4 alkyl esters of acrylic acid or of methacrylic acid and can be comprised of 25-60 weight% (meth)acrylate monomers having an anionic group in the alkyl radial; (b) extruding the mixture, and; (c) comminuting the extrudate to form a granule or powder. The inventive method is characterized in that the active ingredient is the salt of an alk. substance, and in that the pH value, which can be measured on the obtained powder or granule, is equal to or less than pH 7.0. The invention also relates to pharmaceutical dosage forms or precursors thereof, which can be produced using the inventive method. Thus a hot melt compound was prepared by coextruding 50 mass parts Verapamil HCl and 50 mass parts Eudragit L 100-55, then 160 g of the ground hot melt compound was mixed with 230 g lactose, 180 g Avicel PH 102, 30 g Explotab and 3 g magnesium stearate and pressed to tablets. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Product Details of 86393-32-0

The Article related to melt extrusion coextrusion salt drug methacrylate copolymer verapamil hydrochloride, Pharmaceuticals: Formulation and Compounding and other aspects.Product Details of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 19, 2017, Parikh, Nilesh; Hite, William published a patent.COA of Formula: C17H21ClFN3O4 The title of the patent was Topical ciprofloxacin compositions with antibacterial activity. And the patent contained the following:

Embodiments of the invention provide pharmaceutical compositions of ciprofloxacin formulated for topical application to a body surface and for having at least localized antibacterial activity at body sites that comprise, e.g., an ear canal, an oral cavity, a pharyngeal cavity, a nasal cavity, a pulmonary cavity, a vaginal cavity, a rectal cavity, a mucosal surface, a dermal surface, an ophthalmic surface, and a fingernail surface. In some embodiments, the compositions are further formulated for localized anti-inflammatory activity, anti-fungal activity, anti-viral activity, or combinations thereof. Such compositions possess a therapeutically effective amount of a non-betaine form ciprofloxacin (e.g., ciprofloxacin hydrochloride monohydrate); one of a pH adjusting agent and a preservative; water; and a pH from about 5.5 to about 10. In some embodiments, such compositions may be free or free of added skin permeation enhancer and/or contain a betaine form ciprofloxacin. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).COA of Formula: C17H21ClFN3O4

The Article related to ciprofloxacin topical antibacterial antiinflammatory antifungal permeation enhancer, Pharmaceuticals: Formulation and Compounding and other aspects.COA of Formula: C17H21ClFN3O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 19, 2016, Parikh, Nilesh; Hite, William Crawford published a patent.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Topical ciprofloxacin compositions with antibacterial activity. And the patent contained the following:

Embodiments of the invention provide pharmaceutical compositions of ciprofloxacin formulated for topical application to a body surface and for having at least localized antibacterial activity at body sites that comprise, e.g., an ear canal, an oral cavity, a pharyngeal cavity, a nasal cavity, a pulmonary cavity, a vaginal cavity, a rectal cavity, a mucosal surface, a dermal surface, an ophthalmic surface, and a fingernail surface. In some embodiments, the compositions are further formulated for localized anti-inflammatory activity, anti-fungal activity, anti-viral activity, or combinations thereof. Such compositions possess a therapeutically effective amount of a non-betaine form ciprofloxacin (e.g., ciprofloxacin hydrochloride monohydrate); one of a pH adjusting agent and a preservative; water; and a pH from about 5.5 to about 10. In some embodiments, such compositions may be free or free of added skin permeation enhancer and/or contain a betaine form ciprofloxacin. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to ciprofloxacin topical antibacterial antiinflammatory antifungal permeation enhancer, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Kumar, G. Suresh; Govindan, R.; Girija, E. K. published an article in 2014, the title of the article was In situ synthesis, characterization and in vitro studies of ciprofloxacin loaded hydroxyapatite nanoparticles for the treatment of osteomyelitis.Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate And the article contains the following content:

Bioactive materials in combination with antibiotics are widely developed for the treatment of osteomyelitis which play a dual role: as bone substitutes at the affected site and as local drug delivery systems for antibiotic delivery. In the present study, a series of ciprofloxacin loaded hydroxyapatite (HA) nanoparticles with sustained and prolonged release behavior has been synthesized by an in situ precipitation method. The amount of ciprofloxacin loaded on HA nanoparticles can be easily adjusted by changing the initial concentration during the synthesis. It was observed that as the loaded concentration of ciprofloxacin increases the release is sustained and prolonged. The in situ loading of ciprofloxacin onto HA nanoparticles does not significantly affect the bioactivity and cytocompatibility of HA whereas it provides antibacterial activity to HA against S. aureus and E. coli that causes osteomyelitis. Consequently synthesized ciprofloxacin loaded HA nanoparticles can be potential candidates for the treatment of osteomyelitis. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to ciprofloxacin hydroxyapatite nanoparticle osteomyelitis antibacterial biocompatibility, Pharmaceuticals: Formulation and Compounding and other aspects.Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 18, 2022, Gao, Jing; Tan, Shaojie; Wang, Lu published a patent.Synthetic Route of 86393-32-0 The title of the patent was A kind of flexible fiber medicine box for intelligently releasing medicine and its preparation and application.. And the patent contained the following:

The invention relates to a flexible fiber medicine box for intelligently releasing medicine and its preparation and application. The preparation process of the medicine box is as follows: First, the porogen and the macromol. polymer are successively added to the organic solvent and after being mixed uniformly, the nanofiber membrane is prepared by electrospinning as a spinning solution The nanofiber membrane is then put into the Tris-hydrochloric acid buffer solution containing dopamine for modification treatment to obtain a polydopamine-modified nanofiber membrane. Then, the polydopamine-modified nanofiber membrane is placed in a mixed solution for grafting reaction to obtain a switch-loaded fiber membrane. Finally, the switch-loaded fiber membrane is washed and dried to obtain a flexible fiber medicine box. The kit includes porous fibers. PMAA is chem. grafted at the holes on the porous fibers. The prepared medicine box is loaded with medicine, and then the drug release test is carried out in the environment of pH 7.0 to 7.4, the medicine box will not release suddenly within the first 4 to 6 h, and the amount of drug release increases with the pH value of the drug release environment decreased and gradually increased. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Synthetic Route of 86393-32-0

The Article related to ciprofloxacin hydrochloride monohydrate dopamine polydopamine fiber medicine box electrospinning, Pharmaceuticals: Formulation and Compounding and other aspects.Synthetic Route of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics